Is there a Mounjaro KwikPen in Canada?

Yes. Health Canada's Drug Product Database lists six Mounjaro KwikPen products marketed since December 10, 2024. Each pen holds four weekly doses.

What is the difference between the Mounjaro KwikPen and the vial?

The KwikPen is a multi-dose pen with four weekly doses and contains benzyl alcohol as a preservative. The vials are single-dose. Both are Mounjaro (tirzepatide) for type 2 diabetes.

Is the Mounjaro KwikPen the same as the Zepbound KwikPen?

Same molecule and similar multi-dose pen design; different brands and approved uses. Zepbound in Canada is KwikPen only (no vials). See Mounjaro vs Zepbound.

When did the Mounjaro KwikPen launch in Canada?

Health Canada's Drug Product Database lists six Mounjaro KwikPen products as marketed since December 10, 2024.

Mounjaro KwikPen in Canada: Pens vs Vials

Mounjaro KwikPen in Canada: how the multi-dose pen differs from vials and single-dose pens, Health Canada DINs, and how it compares with Zepbound. No dosing.

Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →

Short answer

Yes. In Canada, Mounjaro (tirzepatide for type 2 diabetes) is sold as a multi-dose KwikPen as well as single-dose vials. Health Canada's Drug Product Database lists six MOUNJARO KWIKPEN MULTIDOSE PREFILLED PEN products, all marketed as of December 10, 2024 (DINs 02551950, 02551969, 02551977, 02551985, 02551993 and 02552000; drug codes 104065 to 104070; re-checked November 6, 2026). Each pen holds four weekly doses and contains benzyl alcohol as a preservative. Mounjaro is not a weight-loss brand page: it is approved for type 2 diabetes in adults, and since June 2026 also for ages 10 to 17 with type 2 diabetes. Zepbound, the tirzepatide weight-management brand, is sold in Canada as a KwikPen only (no vials). Not medical advice. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance. Last reviewed November 6, 2026.

Formats on the Canadian market

From Health Canada's Drug Product Database and the Canadian Mounjaro product monograph (checked November 6, 2026).

Format	Status in Canada	Notes
Mounjaro KwikPen (multi-dose prefilled pen)	Six strengths marketed since December 10, 2024	Four weekly doses per pen; benzyl alcohol preservative
Mounjaro single-dose vials	Marketed since October 2023	One dose per vial
Mounjaro single-dose prefilled pens	Approved; not marketed	Listed in the DPD with Approved status
Zepbound KwikPen	Marketed (weight-management brand)	KwikPen only; no vials. See Mounjaro vs Zepbound and Zepbound in Canada

KwikPen vs vial

The KwikPen is a multi-dose pen: one pen is designed to deliver four once-weekly doses. The vials are single-dose. Both contain tirzepatide for type 2 diabetes under the Mounjaro brand. The monograph lists benzyl alcohol as a preservative in the KwikPen; people with a known allergy to benzyl alcohol should raise that with their prescriber or pharmacist. This page does not cover injection technique or reconstitution. Local injection-site reactions are covered separately: injection-site reactions.

Same as the Zepbound KwikPen?

Same device class and same active ingredient (tirzepatide), different approved use and brand. Mounjaro is for type 2 diabetes; Zepbound is for chronic weight management and for obstructive sleep apnea in adults with obesity. In Canada Zepbound is sold only as a KwikPen (no vials), while Mounjaro offers both vials and the KwikPen. Coverage, who can be prescribed which brand, and provincial listings differ. Overviews: Mounjaro in Canada, Zepbound in Canada and Mounjaro vs Zepbound.

Side effects and warnings

Side effects follow the tirzepatide class (mainly stomach and bowel symptoms), with the same serious warnings as other Mounjaro labelling. Full trial rates and Canadian monograph detail: Mounjaro side effects. Benzyl alcohol in the KwikPen is listed as a possible cause of allergic reactions. For rash, hives or itching see GLP-1 rash and itching.

More confessions from the archive

Community Q&A

Is there a Mounjaro KwikPen in Canada?: Yes. Health Canada's Drug Product Database lists six Mounjaro KwikPen products marketed since December 10, 2024. Each pen holds four weekly doses.
What is the difference between the Mounjaro KwikPen and the vial?: The KwikPen is a multi-dose pen with four weekly doses and contains benzyl alcohol as a preservative. The vials are single-dose. Both are Mounjaro (tirzepatide) for type 2 diabetes.
Is the Mounjaro KwikPen the same as the Zepbound KwikPen?: Same molecule and similar multi-dose pen design; different brands and approved uses. Zepbound in Canada is KwikPen only (no vials). See Mounjaro vs Zepbound.
Does this page give dosing advice?: Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
When did the Mounjaro KwikPen launch in Canada?: Health Canada's Drug Product Database lists six Mounjaro KwikPen products as marketed since December 10, 2024.
Does the Mounjaro KwikPen contain benzyl alcohol?: Yes. The Canadian monograph lists benzyl alcohol as a preservative in the multi-dose KwikPen.

Sources

Last reviewed November 6, 2026. Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.